Open-label, randomized study of two doses of GSK2857916 in participants with relapsed / refractory multiple myeloma who have failed prior treatment of an anti-CD38 antibody and are refractory to an immunomodulatory agent and a proteasome inhibitor


This trial is active but is no longer accepting patients.

Trial Overview

Am I Eligible?

Participating US Centers

No Centers To Display

There are no active centers to display for this trial. Please call us at (888) 828-2206 and we'll help answer any questions that you may have.

Additional Information
Trial Phase

Phase 2

Trial Enrollment

155 sparks required

Trial Sponsors
  • GlaxoSmithKline
Trial Identifiers

Need Help?

(888) 828-2206

Weekdays 9am - 5pm EST